2-chloro-3-((3-(2-nitrophenyl)prop-2-ynyloxy)(thiophen-2-yl)methyl)pyridine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-3-((3-(2-nitrophenyl)prop-2-ynyloxy)(thiophen-2-yl)methyl)pyridine
• 化学式: C₁₉H₁₃ClN₂O₃S
• 分子量: 384.843
• InChiKey: UWUFLQMMTOXVTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  65.26
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  2-氯-3-吡啶甲醛 在 copper(l) iodide 、 palladium 10% on activated carbon 、 potassium carbonate 、 magnesium 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 反应 26.5h， 生成 2-chloro-3-((3-(2-nitrophenyl)prop-2-ynyloxy)(thiophen-2-yl)methyl)pyridine
  参考文献：
  名称：

  Synthesis and in vitro anti-proliferative effects of 3-(hetero)aryl substituted 3-[(prop-2-ynyloxy)(thiophen-2-yl)methyl]pyridine derivatives on various cancer cell lines

  摘要：

  A series of 3-(hetero) aryl substituted 3-[(prop-2-ynyloxy)(thiophen-2-yl)methyl]pyridine derivatives were designed as potential anticancer agents. These compounds were conveniently prepared by using Pd/C-Cu mediated Sonogashira type coupling as a key step. Many of these compounds were found to be promising when tested for their in vitro anti-proliferative properties against six cancer cell lines. All these compounds were found to be selective towards the growth inhibition of cancer cells with IC50 values in the range of 0.9-1.7 mu M (against MDA-MB 231 and MCF7 cells), comparable to the known anticancer drug doxorubicin. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.044

文献信息

• Synthesis and in vitro anti-proliferative effects of 3-(hetero)aryl substituted 3-[(prop-2-ynyloxy)(thiophen-2-yl)methyl]pyridine derivatives on various cancer cell lines
  作者：Upendar Reddy Chamakura、E. Sailaja、Balakrishna Dulla、Arunasree M. Kalle、S. Bhavani、D. Rambabu、Ravikumar Kapavarapu、M.V. Basaveswara Rao、Manojit Pal

  DOI：10.1016/j.bmcl.2014.01.044

  日期：2014.3

  A series of 3-(hetero) aryl substituted 3-[(prop-2-ynyloxy)(thiophen-2-yl)methyl]pyridine derivatives were designed as potential anticancer agents. These compounds were conveniently prepared by using Pd/C-Cu mediated Sonogashira type coupling as a key step. Many of these compounds were found to be promising when tested for their in vitro anti-proliferative properties against six cancer cell lines. All these compounds were found to be selective towards the growth inhibition of cancer cells with IC50 values in the range of 0.9-1.7 mu M (against MDA-MB 231 and MCF7 cells), comparable to the known anticancer drug doxorubicin. (C) 2014 Elsevier Ltd. All rights reserved.